Synergistic antifungal effect of lactoferrin with azole antifungals against candida albicans and a proposal for a new treatment method for invasive candidiasis

Japanese Journal of Infectious Diseases

Volumn 64, Issue 4, 2011, Pages 292-296

  Kobayashi, Tsutomu ^a   Kakeya, Hiroshi ^a   Miyazaki, Taiga ^a   Izumikawa, Koichi ^a   Yanagihara, Katsunori ^a   Ohno, Hideaki ^c   Yamamoto, Yoshihiro ^a   Tashiro, Takayoshi ^b   Kohno, Shigeru ^a  

^a Department of Molecular Microbiology and Immunology ^*  (Japan)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ERGOSTEROL; FLUCONAZOLE; ITRACONAZOLE; LACTOFERRIN;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CONTROLLED STUDY; DRUG DETERMINATION; DRUG POTENTIATION; DRUG UPTAKE; FUNGAL STRAIN; FUNGUS GROWTH; FUNGUS HYPHAE; FUNGUS MUTANT; GROWTH INHIBITION; INVASIVE CANDIDIASIS; IRON CHELATION; ISOTOPE LABELING; NONHUMAN;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS, INVASIVE; DRUG COMBINATIONS; DRUG RESISTANCE, FUNGAL; DRUG SYNERGISM; FLUCONAZOLE; IRON; ITRACONAZOLE; LACTOFERRIN; MICROBIAL SENSITIVITY TESTS;

EID: 79960975803     PISSN: 13446304     EISSN: 18842836     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Horn, D.L., Neofytos, D., Anaissie, E.J., et al. (2009): Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin. Infect. Dis., 48, 1695-1703.
2. Venkatesh, M.P. and Rong, L. (2008): Human recombinant lactoferrin acts synergistically with antimicrobials commonly used in neonatal practice against coagulase-negative staphylococci and Candida albicans causing neonatal sepsis. J. Med. Microbiol., 57, 1113-1121.
3. Wakabayashi, H., Abe, S., Teraguchi, S., et al. (1998): Inhibition of hyphal growth of azole-resistant strains of Candida albicans by triazole antifungal agents in the presence of lactoferrin-related compounds. Antimicrob. Agents Chemother., 42, 1587-1591.
4. Miyazaki, Y., Geber, A., Miyazaki, H., et al. (1999): Cloning, sequencing, expression and allelic sequence diversity of ERG3 (C-5 sterol desaturase gene) in Candida albicans. Gene, 236, 43-51.
5. Vanden Bossche, H., Marichal, P., Gorrens, J., et al. (1990): Mutation in cytochrome P-450-dependent 14 alpha-demethylase results in decreased affinity for azole antifungals. Biochem. Soc. Trans., 18, 56-59.
6. Albertson, G.D., Niimi, M., Cannon, R.D., et al. (1996): Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob. Agents Chemother., 40, 2835-2841.
7. Miyazaki, T., Miyazaki, Y., Izumikawa, K., et al. (2006): Fluconazole treatment is effective against a Candida albicans erg3/erg3 mutant in vivo despite in vitro resistance. Antimicrob. Agents Chemother., 50, 580-586.
8. Warnock, D.W., Johnson, E.M., Richardson, M.D., et al. (1983): Modified response to ketoconazole of Candida albicans from a treatment failure. Lancet, 1, 642-643.
9. Kakeya, H., Miyazaki, Y., Miyazaki, H., et al. (2000): Genetic analysis of azole resistance in the Darlington strain of Candida albicans. Antimicrob. Agents Chemother., 44, 2985-2990.
10. Sanglard, D., Kuchler, K., Ischer, F., et al. (1995): Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents Chemother., 39, 2378-2386.
11. Clinical Laboratory Standards Institute (2008): Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard-3rd ed. M27-A3. Clinical Laboratory Standards Institute, Wayne, Pa.
12. Barthe, C., Galabert, C., Guy-Crotte, O., et al. (1989): Plasma and serum lactoferrin levels in cystic fibrosis. Relationship with the presence of cystic fibrosis protein. Clin. Chim. Acta, 181, 183-188.
13. Eliopoulos, G.M. and Moellering, R.C. (1991): Antimicrobial combinations. p. 432-492. In Lorian, V. (ed.), Antibiotics in Laboratory Medicine. 3rd ed. Williams & Wilkins, Baltimore.
14. Johnson, M.D., MacDougall, C., Ostrosky-Zeichner, L. et al. (2004): Combination antifungal therapy. Antimicrob. Agents Chemother., 48, 693-715.
15. Bennett, J.E., Izumikawa, K. andMarr, K.A. (2004): Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob. Agents Chemother., 48, 1773-1777.
16. Tomita, M., Yamauchi, K., Teraguchi, S., et al. (1998): Host defensive effects of orally administered bovine lactoferrin. Adv. Exp. Med. Biol., 443, 189-197.
17. Bellamy, W., Wakabayashi, H., Takase, M., et al. (1993): Killing of Candida albicans by lactoferricin B, a potent antimicrobial peptide derived from the N-terminal region of bovine lactoferrin. Med. Microbiol. Immunol., 182, 97-105.
18. Kuipers, M.E., de Vries, H.G., Eikelboom, M.C., et al. (1999): Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates. Antimicrob. Agents Chemother., 43, 2635-2641.
19. Goldberg, S., Doyle, R.J. and Rosenberg, M. (1990): Mechanism of enhancement of microbial cell hydrophobicity by cationic polymers. J. Bacteriol., 172, 5650-5654.
20. Zasloff, M. (2002): Antimicrobial peptides of multicellular organisms. Nature, 415, 389-395.
21. van der Strate, B.W., Harmsen, M.C., The, T.H., et al. (1999): Plasma lactoferrin levels are decreased in end-stage AIDS patients. Viral Immunol., 12, 197-203.